|
1
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar :
|
|
2
|
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S and Vigneri R: Worldwide increasing incidence of
thyroid cancer: Update on epidemiology and risk factors. J Cancer
Epidemiol. 2013:9652122013.PubMed/NCBI
|
|
3
|
Yang L, Yuan Y, Sun T, Li H and Wang N:
Population-based cancer incidence analysis in Beijing, 2008–2012.
Chin J Cancer Res. 27:13–21. 2015.PubMed/NCBI
|
|
4
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bleul CC, Fuhlbrigge RC, Casasnovas JM,
Aiuti A and Springer TA: A highly efficacious lymphocyte
chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med.
184:1101–1109. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Caruz A, Samsom M, Alonso JM, Alcami J,
Baleux F, Virelizier JL, Parmentier M and Arenzana-Seisdedos F:
Genomic organization and promoter characterization of human CXCR4
gene. FEBS Lett. 426:271–278. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gupta SK and Pillarisetti K: Cutting edge:
CXCR4-Lo: molecular cloning and functional expression of a novel
human CXCR4 splice variant. J Immunol. 163:2368–2372.
1999.PubMed/NCBI
|
|
8
|
Burns JM, Summers BC, Wang Y, Melikian A,
Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ,
et al: A novel chemokine receptor for SDF-1 and I-TAC involved in
cell survival, cell adhesion, and tumor development. J Exp Med.
203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balabanian K, Lagane B, Infantino S, Chow
KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M and
Bachelerie F: The chemokine SDF-1/CXCL12 binds to and signals
through the orphan receptor RDC1 in T lymphocytes. J Biol Chem.
280:35760–35766. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lu DY, Tang CH, Yeh WL, Wong KL, Lin CP,
Chen YH, Lai CH, Chen YF, Leung YM and Fu WM: SDF-1alpha
up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and
NF-kappaB-dependent pathway in microglia. Eur J Pharmacol.
613:146–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roland J, Murphy BJ, Ahr B, Robert-Hebmann
V, Delauzun V, Nye KE, Devaux C and Biard-Piechaczyk M: Role of the
intra-cellular domains of CXCR4 in SDF-1-mediated signaling. Blood.
101:399–406. 2003. View Article : Google Scholar
|
|
12
|
Levoye A, Balabanian K, Baleux F,
Bachelerie F and Lagane B: CXCR7 heterodimerizes with CXCR4 and
regulates CXCL12-mediated G protein signaling. Blood.
113:6085–6093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sierro F, Biben C, Martínez-Muñoz L,
Mellado M, Ransohoff RM, Li M, Woehl B, Leung H, Groom J, Batten M,
et al: Disrupted cardiac development but normal hematopoiesis in
mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc
Natl Acad Sci USA. 104:14759–14764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boldajipour B, Mahabaleshwar H, Kardash E,
Reichman-Fried M, Blaser H, Minina S, Wilson D, Xu Q and Raz E:
Control of chemokine-guided cell migration by ligand sequestration.
Cell. 132:463–473. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dambly-Chaudière C, Cubedo N and Ghysen A:
Control of cell migration in the development of the posterior
lateral line: Antagonistic interactions between the chemokine
receptors CXCR4 and CXCR7/RDC1. BMC Dev Biol. 7:232007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang J, Shiozawa Y, Wang J, Wang Y, Jung
Y, Pienta KJ, Mehra R, Loberg R and Taichman RS: The role of CXCR7/
RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J
Biol Chem. 283:4283–4294. 2008. View Article : Google Scholar
|
|
17
|
Sun YX, Schneider A, Jung Y, Wang J, Dai
J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, et al: Skeletal
localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis
blocks prostate cancer metastasis and growth in osseous sites in
vivo. J Bone Miner Res. 20:318–329. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miao Z, Luker KE, Summers BC, Berahovich
R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A,
Luker GD, et al: CXCR7 (RDC1) promotes breast and lung tumor growth
in vivo and is expressed on tumor-associated vasculature. Proc Natl
Acad Sci USA. 104:15735–15740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chung SY, Park ES, Park SY, Song JY and
Ryu HS: CXC motif ligand 12 as a novel diagnostic marker for
papillary thyroid carcinoma. Head Neck. 36:1005–1012. 2014.
View Article : Google Scholar
|
|
21
|
Jung YY, Park IA, Kim MA, Min HS, Won JK
and Ryu HS: Application of chemokine CXC motif ligand 12 as a novel
diagnostic marker in preoperative fine-needle aspiration biopsy for
papillary thyroid carcinoma. Acta Cytol. 57:447–454. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Sun DX, Teng XY, Xu WX, Meng XP and
Wang BS: Expression of stromal cell-derived factor 1 and CXCR7 in
papillary thyroid carcinoma. Endocr Pathol. 23:247–253. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wagner PL, Moo TA, Arora N, Liu YF,
Zarnegar R, Scognamiglio T and Fahey TJ III: The chemokine
receptors CXCR4 and CCR7 are associated with tumor size and
pathologic indicators of tumor aggressiveness in papillary thyroid
carcinoma. Ann Surg Oncol. 15:2833–2841. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu CL, Guo J, Gu J, Ge D, Hou YY, Lin ZW
and Ding JY: CXCR4 heterogeneous expression in esophageal squamous
cell cancer and stronger metastatic potential with CXCR4-positive
cancer cells. Dis Esophagus. 27:294–302. 2014. View Article : Google Scholar
|
|
25
|
De Falco V, Guarino V, Avilla E,
Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro
M and Melillo RM: Biological role and potential therapeutic
targeting of the chemokine receptor CXCR4 in undifferentiated
thyroid cancer. Cancer Res. 67:11821–11829. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hwang JH, Hwang JH, Chung HK, Kim DW,
Hwang ES, Suh JM, Kim H, You KH, Kwon OY, Ro HK, et al: CXC
chemokine receptor 4 expression and function in human anaplastic
thyroid cancer cells. J Clin Endocrinol Metab. 88:408–416. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ghosh MC, Makena PS, Gorantla V, Sinclair
SE and Waters CM: CXCR4 regulates migration of lung alveolar
epithelial cells through activation of Rac1 and matrix
metalloproteinase-2. Am J Physiol Lung Cell Mol Physiol.
302:L846–L856. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ying X, Jing L, Ma S, Li Q, Luo X, Pan Z,
Feng Y and Feng P: GSK3β mediates pancreatic cancer cell invasion
in vitro via the CXCR4/MMP-2 pathway. Cancer Cell Int. 15:702015.
View Article : Google Scholar
|
